This summary is generated by an algorithm. If you find any mistakes, let us know.

Biopharma Biotechnology Life Science Machine Learning Manufacturing North America

AbSci Announces Strategic Investment

– AbSci announced a strategic equity investment by Merck Global Health Innovation Fund.
– Merck GHI is a fund of Merck Research Laboratories.
– AbSci is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology that reinvents the biopharmaceutical drug discovery process.

Source
Biometrics Biopharma Biotechnology North America

ABclonal Biotechnology Completes $93 Million Series C Financing

– ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital.
– Other new and existing shareholders, such as Sigma Square Capital, Kinghall Ventures, and Lucion Capital, participated in the new round.
– ABclonal Biotechnology, parent company of Massachusetts-based life science research and diagnostic reagents manufacturer, ABclonal Technology, will use the additional funding to accelerate the company’s research and development pipeline for in vitro diagnostic raw materials and rapidly expand production capabilities of its research reagent products and services.
– ABclonal is also currently in talks to acquire a contract research organization focused on single-cell-based monoclonal antibody development. This will be the company’s first step toward using the $92.

Source
Biopharma Biotechnology Europe Therapeutics

EMERCell Receives Strategic Investment from Onward Therapeutics

Onward Therapeutics from Montpellier, France, invested in EMERCell.
– The amount of the deal was not disclosed.
– EMERCell SAS is a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
Onward Therapeutics became the majority shareholder after it invested in EMERCell SAS.

Source
Biopharma Biotechnology Developer Tools Europe Health Care

GeneQuine Biotherapeutics Raises Over Euro 9M in Series A and Non-Dilutive Funding

– GeneQuine is a Hamburg, Germany-based biotech company focused on the development of gene therapy for musculoskeletal disorders.
– The company raised a total of €9.05m in Series A and non-dilutive funding.
– The round was led by Pacira BioSciences, Inc. (Nasdaq: PCRX), with participation from High-Tech Gründerfonds, Noshaq SA, and Samum Vermögensverwaltungs GmbH.

Source
Biopharma Biotechnology North America Therapeutics

Sagimet Biosciences Raises $80M in Crossover Financing

– Sagimet Biosciences, a San Mateo, Calif.-based clinical-stage biotechnology company, raised $80m in crossover financing.
– The round was led by an undisclosed public equity healthcare investment fund with participation from existing investors (including Ascletis, Kleiner Perkins, New Enterprise Associates (NEA) and Rock Springs Capital) along with new investors (Altium Capital, HM Capital, Invus and PFM Health Sciences).
– The company intends to use the funds to advance its lead program, TVB-2640 for NASH, to explore additional indications, to file an IND on a second FASN inhibitor, TVB-3567, by the end of 2021.

Source
Biopharma Biotechnology Health Care Medical North America Pharmaceutical

Day One Biopharmaceuticals Inks $130M Series B Financing

– Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating therapies for children and adults with cancer, announced a $130 million Series B financing.
– The financing was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors. Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.

Source
Biopharma Biotechnology Health Care Medical North America Pharmaceutical

Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children

– Day One Biopharmaceuticals announced a $130m Series B financing round bringing total investment in the company to $190m.
– The round was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors.
– Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.
– Proceeds from the Series B financing will allow Day One to accelerate and expand its search and evaluation capabilities, support drug development efforts and continue advancing commercial launch plans for the Company’s lead program, DAY101.

Source
Biopharma Biotechnology Health Care North America Pharmaceutical Therapeutics

ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing

– ImmunoMet Therapeutics received IND clearance and orphan drug designation from the U.S. FDA for IM156 in idiopathic pulmonary fibrosis (IPF).
– The Company also announced the closing of $7.0M in new financing by both existing and new investors that will be used, in part, to fund the Phase 1 program.
– The Company plans to initiate a single-site U.S. Phase 1 study in 32 healthy volunteers designed to characterize the safety, tolerability, pharmacokinetics, and effects of IM156 in Q1 2021.
– Data from this Phase 1 study will inform the design of a Phase 2 trial in patients with IPF.

Source
Crunchbase icon

Content report

The following text will be sent to our editors: